
Melanotan 2
$35
In stock
View productThe collagen peptides category holds one product, Melanotan 2, which is not a collagen product; it is labeled for research use only and ships from the USA and Canada to addresses across the United States.
This category holds one product, Melanotan 2, which is not a collagen product, and the catalog carries no collagen supplements. FDA said in 2007 that Melanotan II was not an approved drug, sent a warning letter to a company over its illegal sale as a tanning agent and skin cancer preventive, and recommended that consumers using it stop.12
Melanotan 2 is also filed under sexual health peptides. Its research is mapped in the tanning goal guide, and the skin and hair goal guide covers other compounds studied for skin.
Melanotan 2 ships from the USA and Canada to addresses across the United States; the shipping page has the details. Read the returns page for return terms and the lab results page for testing documents as they become available. Questions about this category can go through the contact page.
No. The only product filed under this name is Melanotan 2, and the catalog holds no collagen products of any kind. The category name follows the catalog's grouping, not the product's chemistry. Other peptides, including GHK-Cu, are listed under anti-aging peptides, and the full range is on the peptides for sale page.
Regulators have recorded serious concerns: FDA's compounding safety page cites published case reports of serious adverse events with melanotan II, including melanoma, posterior reversible encephalopathy syndrome, sympathomimetic toxidrome and priapism.3 The UK medicines regulator received 16 UK reports of suspected adverse reactions to it from 2012 through 2022, and notes that a report does not necessarily mean the product caused the event.5 Health Canada's April 2026 warning about injectable peptides bought online named Melanotan I and II.4 The Melanotan education page covers the reported side effects.
FDA lists melanotan II among substances once in Category 2 for compounding whose nominations were withdrawn, and still sets out its safety concerns on that page.3 FDA says its Pharmacy Compounding Advisory Committee will discuss melanotan II for the 503A bulks list at a meeting before the end of February 2027, along with LL-37, GHK-Cu, dihexa acetate and PEG-MGF.67 As of October 25, 2026, the meeting page still gave no date.6
D2C Peptides sells peptides for laboratory research. Please confirm both statements to continue.